Azita Saleki-Gerhardt - 18 Feb 2026 Form 4 Insider Report for AbbVie Inc. (ABBV)

Reporting relationship: EVP, CHIEF OPERATIONS OFFICER
Issuer ticker: ABBV
Reported as of: 18 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 Feb 2026, 18:35:18 UTC
Prior SEC filing: 14 Aug 2025
Next SEC filing: 03 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ T.O. Odutayo, Attorney-in-Fact for Azita Saleki-Gerhardt

Key filing fact

Azita Saleki-Gerhardt filed Form 4 for AbbVie Inc. (ABBV) on 20 Feb 2026.

Key facts

This page summarizes Azita Saleki-Gerhardt's Form 4 filing for AbbVie Inc. (ABBV).
5 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 20 Feb 2026, 18:35.

Change

Previous filing in this sequence was filed on 14 Aug 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001563545 Primary reporting owner

SALEKI-GERHARDT AZITA

Relationship: EVP, CHIEF OPERATIONS OFFICER
Address: 1 N. WAUKEGAN ROAD, NORTH CHICAGO
Signature: /s/ T.O. Odutayo, Attorney-in-Fact for Azita Saleki-Gerhardt
Signature date: 20 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ABBV transaction

Common Stock, $0.01 par value

Award

Transaction value: $0
Shares: +17,041
Change %: +9.6%
Price: $0.000000
Shares after: 194,333
Date: 18 Feb 2026
Ownership: Direct
Footnotes: F1

ABBV transaction

Common Stock, $0.01 par value

Award

Transaction value: $0
Shares: +6,058
Change %: +3.1%
Price: $0.000000
Shares after: 200,391
Date: 18 Feb 2026
Ownership: Direct
Footnotes: F2

ABBV transaction

Common Stock, $0.01 par value

Award

Transaction value: $0
Shares: +7,074
Change %: +3.5%
Price: $0.000000
Shares after: 207,465
Date: 18 Feb 2026
Ownership: Direct
Footnotes: F3

ABBV transaction

Common Stock, $0.01 par value

Award

Transaction value: $0
Shares: +6,638
Change %: +3.2%
Price: $0.000000
Shares after: 214,103
Date: 18 Feb 2026
Ownership: Direct
Footnotes: F4

ABBV holding

Common Stock, $0.01 par value

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 2,706
Date: 18 Feb 2026
Ownership: Profit sharing trust
Footnotes: F5

ABBV holding

Common Stock, $0.01 par value

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 3,873
Date: 18 Feb 2026
Ownership: By spouse
Footnotes: F6

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ABBV transaction Derivative

Option (Right to Buy)

Award

Transaction value: $0
Shares: +20,312
Change %
Price: $0.000000
Shares after: 20,312
Date: 18 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,312
Exercise price: $230.04
Footnotes: F7

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 7 footnotes

Footnote F1

Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.

Footnote F2

Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.

Footnote F3

Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.

Footnote F4

Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 13, 2025. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.

Footnote F5

Balance in AbbVie Savings program as of February 20, 2026. Balance includes shares acquired pursuant to a dividend reinvestment feature.

Footnote F6

The reporting person disclaims beneficial ownership of all securities held by her spouse.

Footnote F7

Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 6,771 on February 18, 2027, 6,771 on February 18, 2028, and 6,770 on February 18, 2029.